Compare BioNano Genomics Inc (BNGO) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Union Pacific Corporation — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Union Pacific Corporation trades at $288.34 (market cap $171.17B). The key difference: Union Pacific Corporation is far larger — about 12967.4× BioNano Genomics Inc's market cap, and Union Pacific Corporation pays a 1.91% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | UNP | |
|---|---|---|
Market Cap | $13.20M | $171.17B |
Sector | Health | Industrials |
52-Week High | $4.92 | $289.13 |
52-Week Low | $1.09 | $214.91 |
Enterprise Value | $15.81M | $201.64B |
Dividend Yield | — | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Union Pacific (UNP) trades at $289.13, up 0.76% with a bullish technical signal. The company shows strong profitability with 29.2% net margins and 40.69% ROE, though valuation multiples remain elevated. Recent earnings beat expectations in Q1 2026, and the proposed Norfolk Southern merger represents a significant growth catalyst. Cash flow generation remains robust at $9.29B from operations in 2025.
Outlook remains positive with analyst consensus at Buy and $304.23 price target, though regulatory hurdles for the merger and elevated RSI levels pose near-term risks. The stock offers dividend growth potential with stable operational performance, but faces headwinds from industry consolidation concerns and potential legal liabilities from ongoing class action litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
